Glioblastoma (GBM) IDH-wildtype, classified as WHO grade IV and characterized by wild-type IDH1, has now emerged as a distinct entity, significantly streamlining research and guiding the development of novel therapies (1–5). This evidence concerns the gene IDH1 and glioblastoma.